ArticleScientific reports2025
I-BET151 modulates NLRP3 inflammasome-mediated pyroptosis and exhibits anti-inflammatory activity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have shown that inhibiting the aberrant activation of NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasomes can alleviate the onset and progression of various inflammatory diseases. This study investigated the anti-inflammatory mechanism of I-BET151 and its therapeutic effects on colitis and acute lung injury. Through screening of the compound library, it was found that I-BET151 can inhibit NLRP3 inflammasome activation. Enzyme-linked immunosorbent assay (ELISA), high-content screening, immunoprecipitation (IP), Western blot (WB), immunofluorescence etc., were used to study the anti-inflammatory activity and mechanism of action of I-BET151; the therapeutic effects of I-BET151 were assessed in DSS-induced acute colitis and CLP-induced sepsis-associated acute lung injury (SALI) models in mice. The results showed that I-BET151 could inhibit IL-1β secretion and cell apoptosis. Mechanistically, I-BET151 did not affect mitochondrial damage or reactive oxygen species (ROS) production, but exerted its anti-inflammatory activity by targeting the NLRP3 protein to inhibit NLRP3 inflammasome assembly. In vivo experiments demonstrated that I-BET151 exhibited promising therapeutic effects in both DSS-induced acute colitis and CLP-induced SALI models in mice. In conclusion, I-BET151 is a promising candidate for the treatment of colitis and acute lung injury, primarily exerting its biological activity through the targeting of NLRP3 protein.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.